Highlights

  • Zycov D likely to be available from October
  • Deemed safe for children above 12 years of age
  • 3 doses with 28 day intervals recommended

Latest news

Future Netwings Solution Enhances Service Delivery with the Business Continuity Policy

Future Netwings Solution Enhances Service Delivery with the Business Continuity Policy

India-UK trade deal likely by May 1; Europe deal expected by year-end

India-UK trade deal likely by May 1; Europe deal expected by year-end

VerSe Innovation Appoints Prasanna Prasad as Chief Product and Technology Officer to Accelerate AI-Led Product and Platform Innovation

VerSe Innovation Appoints Prasanna Prasad as Chief Product and Technology Officer to Accelerate AI-Led Product and Platform Innovation

Changing Aspirations of Premium Homebuyers in NCR

Changing Aspirations of Premium Homebuyers in NCR

Airfloa Rail Technology's FY26 Business Update and Strategic Direction

Airfloa Rail Technology's FY26 Business Update and Strategic Direction

Sanjay Khanna Appointed as Chairman & Managing Director of BPCL

Sanjay Khanna Appointed as Chairman & Managing Director of BPCL

Galgotias University Placement Report: 4700+ Offers Across Top Recruiters in 2026

Galgotias University Placement Report: 4700+ Offers Across Top Recruiters in 2026

"Be the same loving brother you are to me...": Sanjay Dutt pens heartfelt birthday note for Anant Ambani

"Be the same loving brother you are to me...": Sanjay Dutt pens heartfelt birthday note for Anant Ambani

Meet ZyCoV-D: The world’s first DNA Covid-19 vaccine; everything you need to know about the new vaccine

The shot is “the world’s first and India’s indigenously developed DNA-based vaccine for Covid-19 to be administered in humans including children and adults 12 years and above.”

Meet ZyCoV-D: The world’s first DNA Covid-19 vaccine; everything you need to know about the new vaccine

Zydus Cadila's covid vaccine ZyCoV-D is set to be launched in India in October and is deemed for safe for kids above 12. This 'third-generation triple dose vaccine' could just be the answer to fill the gap of 100 crore doses required by year-end to vaccinate the vast majority of the adult population. Here is everything you need to know about this non-injecting, DNA vaccine which even children above 12 can take.

Meet Cadila’s ZyCoV-D

  • It is the world’s first DNA vaccine to protect against Covid 19. Requires a triple dose for immunity and showcased 67% efficacy in trials. The vaccine is deemed safe for children above the age of 12.

What kind of vaccine is it? How is it different than Covishield and Covaxin?

  • Cadila’s ZyCoV-D is a plasmid DNA vaccine that introduces a DNA sequence encoding the antigen in the body and not a weakened form of the pathogen like Covaxin.

How does a DNA vaccine work?

  • Often referred to as the third-generation vaccines, the dose carries the genetic code of the virus that triggers the build up of immunity in one's body.
  • Zydus stated that the plasmid DNA platform is “ideally suited for dealing with Covid-19 as it can be easily adapted to deal with mutations in the virus, such as those already occurring”.

Is a DNA vaccine being used anywhere else in the world?

  • No DNA vaccine has been widely used against any disease so far, but they are more stable and easier to store than mRNA shots (tech used by Pfizer & Moderna)
  • According to the U.S. National Library of Medicine, over 160 different DNA vaccines are currently being tested in human clinical trials in the United States. It is estimated that 62% of these trials are devoted to cancer vaccines and 33% are applied for vaccines against human immunodeficiency virus (HIV).

How many doses does one need?

  • Unlike most other Covid-19 vaccines, which require two doses for full immunity, ZyCoV-D is administered in three doses. The vaccine is also needle-free.
  • The doses will be administered 28 days apart

Needle-free vaccine, how does one get the dose?

  • Doses are given using a device that delivers fluid through a spring-powered jet that penetrates the skin, developed by Pharmajet’s Tropis.
  • Zydus Cadila claims this method of delivery is painless and could also reduce side effects from the jab

Is it safe? What are the trial results showing?

  • The vaccine has been tested on almost 30,000 participants across Phase I, II and III studies, and is the first vaccine in India to be tested on 12 to 18-year-olds. Around 1,000 participants were enrolled in the adolescent age group, among whom the vaccine was found to be safe and well-tolerated, with similar findings in the adult population

ADVERTISEMENT

Up Next

Meet ZyCoV-D: The world’s first DNA Covid-19 vaccine; everything you need to know about the new vaccine

Meet ZyCoV-D: The world’s first DNA Covid-19 vaccine; everything you need to know about the new vaccine

Centre plans to borrow Rs 8.20 lakh cr from market in first half of FY27

Centre plans to borrow Rs 8.20 lakh cr from market in first half of FY27

Reliance denies buying Iranian oil amid US sanctions waiver

Reliance denies buying Iranian oil amid US sanctions waiver

Premium petrol price up Rs 2, industrial diesel up Rs 22; no change in normal petrol, diesel rates

Premium petrol price up Rs 2, industrial diesel up Rs 22; no change in normal petrol, diesel rates

India's GDP expected to register over 8 pc growth in Sep-Dec: Report

India's GDP expected to register over 8 pc growth in Sep-Dec: Report

Govt announces seven measures to help boost exports

Govt announces seven measures to help boost exports

ADVERTISEMENT

editorji-whatsApp

More videos

RBI keeps interest rates on hold after US trade deal boosts outlook

RBI keeps interest rates on hold after US trade deal boosts outlook

RBI proposes to compensate customers up to Rs 25,000 loss due to fraud

RBI proposes to compensate customers up to Rs 25,000 loss due to fraud

RBI raises GDP growth projection of Q1, Q2 of FY27

RBI raises GDP growth projection of Q1, Q2 of FY27

RBI pauses rate cuts, retains interest rate at 5.25 pc

RBI pauses rate cuts, retains interest rate at 5.25 pc

Rupee jumps 122 paise to close at 90.27 against US dollar on India-US trade deal

Rupee jumps 122 paise to close at 90.27 against US dollar on India-US trade deal

Stock markets cheer India-US trade deal: Sensex, Nifty surge 2.5 pc

Stock markets cheer India-US trade deal: Sensex, Nifty surge 2.5 pc

UPI transactions hit record high of Rs 230 lakh crore in 2025-26 till Dec: Govt

UPI transactions hit record high of Rs 230 lakh crore in 2025-26 till Dec: Govt

Explained: India-US trade deal, tariffs and trade benefits

Explained: India-US trade deal, tariffs and trade benefits

Trade deal with US adds momentum to India's growth ambition: Industry leaders

Trade deal with US adds momentum to India's growth ambition: Industry leaders

Rupee jumps 119 paise to 90.30 against the US dollar on India-US trade deal

Rupee jumps 119 paise to 90.30 against the US dollar on India-US trade deal

Editorji Technologies Pvt. Ltd. © 2022 All Rights Reserved.